Jaume Pons - 03 Feb 2022 Form 4 Insider Report for ALX ONCOLOGY HOLDINGS INC (ALXO)

Role: President & CEO, Director
Signature: /s/ Peter Garcia, by power of attorney
Issuer symbol: ALXO
Transactions as of: 03 Feb 2022
Net transactions value: +$35,186
Form type: 4
Filing time: 07 Feb 2022, 07:27:20 UTC
Previous filing: 20 Oct 2021
Next filing: 09 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALXO	Common Stock	Options Exercise	$11,781	+11,900	+2.7%	$0.9900^*	456,724	03 Feb 2022	Direct	F1
transaction	ALXO	Common Stock	Options Exercise	$23,405	+12,254	+2.7%	$1.91	468,978	03 Feb 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALXO	Employee Stock Option (right to buy)	Options Exercise	$0	-11,900	-4.9%	$0.000000	230,279	03 Feb 2022	Common Stock	11,900	$0.9900	Direct	F2
transaction	ALXO	Employee Stock Option (right to buy)	Options Exercise	$0	-12,254	-67%	$0.000000	6,128	03 Feb 2022	Common Stock	12,254	$1.91	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 226 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021.
F2	Shares subject to the option are fully vested and immediately exercisable.
F3	The option is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on June 16, 2019.